FDA delays approval of Pfizers maraviroc

Share this article:

The approval of Pfizer's maraviroc was dealt a blow Wednesday as the drug's maker received an approvable letter from the FDA requesting additional information on the investigational HIV compound.

The FDA had been expected to approve maraviroc this week.
 
Pfizer said in a statement, “We plan to continue discussions with the FDA to address any outstanding questions and finalize the product labeling as soon as possible.”

Pfizer did not elaborate on the approvable letter’s questions or issue a timetable for FDA action.

Maraviroc was granted priority review status in February. Priority review status, which trims time off the standard approval time period, is usually granted to compounds deemed an advance over existing therapies by the FDA.

In April, an FDA panel of outside experts recommended the agency approve maraviroc, citing a need for new HIV treatments. However, some panelists shared concerns about liver damage, heart problems and infection associated with the drug. GlaxoSmithKline stopped work on a similar CCR5 drug after it was found to cause liver problems.
 
Analysts have projected sales of maraviroc, if approved, to reach $500 million by 2011.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...